

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: July 30, 2008 (use as many sheets as necessary)				Complete if Known	
				Application Number	10/714,643
				Filing Date	11/18/2003
				First Named Inventor	Peter A. CROOKS
				Art Unit	1617
				Examiner Name	Yong Soo CHONG
				Attorney Docket Number	069962-0102

JUL 31 2008
 U.S. PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	Cohen ML. Trevor AJ., On the cerebral accumulation of ketamine and the relationship between metabolism of drug and its pharmacological effects, J Pharmacol Exp Ther, 1974, pp. 351-8, vol. 189.	
	C2	Cohen ML., Chan, SL., Way WL., Trevor AJ, Distribution in the brain and metabolism of ketamine in the rat after intravenous administration, Anesthesiology, 1973, pp. 370-376, vol. 39, no. 4.	
	C3	Hustveit O., Maurset A., Oye L., Interaction of chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors, Pharmacol Toxicol, 1995, pp. 355-9, vol. 77.	
	C4	Malinovsky, J.-M., Cozian SA., Lapage JY., Pinaud M., Ketamine and norketamine plasma concentrations after IV and nasal and rectal administration in children, Brit J. Anesth., 1996, pp. 203-7, vol. 77.	
	C5	Marietta MP., Way WL., Castagnoli N., Trevor AJ., On the pharmacology of ketamine enantiomers in the rat, J. Pharmacol Exp Ther, 1977, pp. 157-65, vol. 202, no. 1.	
	C6	Ryder S., Way WL., Trevor AJ., Comparative pharmacology of the optical isomers of ketamine in mice, Eur J Pharmacol, 1978, pp. 15-23, vol. 49.	
	C7	Schuttler J., Zsigmond EK., White PF., Ketamine and its isomers In White PF edition Textbook of Intravenous anesthesia, Baltimore: Williams and Wilkins, 1997, pp. 171-88.	
	C8	Vollenweider FX., Leenders KL., Oye L., Hell D., Angst J., Differential psychopathology and patterns of cerebral glucose utilization produced by S- and R-ketamine in healthy volunteers using positron emission tomography (PET), Eur Neuropharmacol, 1997, pp. 25-38, vol. 7.	
	C9	White PF., Ham J., Way WL., Trevor AJ., Pharmacology of ketamine isomers in surgical patterns, Anesthesiology, 1980, pp. 231-239, vol. 52.	
	C10	Arendt-Nielsen L., Nielsen J., Petersen-Felix S., Schnider TW., Zbinden AM., Effect of racemic mixture and the S(+)-isomer of ketamine on temporal and spatial summation of pain, Br J Anesth, 1996, pp. 652-31, vol. 77.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: July 30, 2008 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/714,643
				Filing Date	11/18/2003
				First Named Inventor	Peter A. CROOKS
				Art Unit	1617
				Examiner Name	Yong Soo CHONG
				Attorney Docket Number	069962-0102
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	C11	Singelyn et al., "Postoperative Analgesia After Total Hip Arthroplasty: IV PCA with Morphine, Patient-Controlled Epidural Analgesia, or Continuous "3-in-1" Block?: A Prospective Evaluation by Our Acute Pain Service in More than 1,300 Patients." Journal of Clinical Anesthesia, 1999, Vol. 11, pages 550-554.		
	C12	Paronis et al., "Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats." Pharmacology, July 1992, Vol. 262, issue 1, pages 1-9.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.